A2Aadenosine receptors and Parkinson's disease severity

Biomarkers of Parkinson's disease: current status and future perspectives

(2012) Jian Wang et al.   DRUG DISCOVERY TODAY

Naturally occurring  -synuclein autoantibody levels are lower in patients with Parkinson disease

(2012) D. Besong-Agbo et al.   NEUROLOGY

The Distinct Role of Medium Spiny Neurons and Cholinergic Interneurons in the D2/A2A Receptor Interaction in the Striatum: Implications for Parkinson's Disease

(2011) A. Tozzi et al.   JOURNAL OF NEUROSCIENCE

Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

(2011) Robert A Hauser et al.   LANCET NEUROLOGY

Adenosine 2A receptor availability in dyskinetic and nondyskinetic patients with Parkinson disease

(2011) A. F. Ramlackhansingh et al.   NEUROLOGY

Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression

(2010) Min Shi et al.   ANNALS OF NEUROLOGY

Biomarkers in Parkinson’s Disease

(2010) John C. Morgan et al.   Current Neurology and Neuroscience Reports

Clinical efficacy of istradefylline (KW-6002) in Parkinson's disease: A randomized, controlled study

(2010) Yoshikuni Mizuno et al.   MOVEMENT DISORDERS

Chronic A2A antagonist treatment alleviates parkinsonian locomotor deficiency in MitoPark mice

(2010) Daniel Marcellino et al.   NEUROBIOLOGY OF DISEASE

A long-term study of istradefylline in subjects with fluctuating Parkinson's disease

(2010) Stewart Factor et al.   PARKINSONISM & RELATED DISORDERS

A2A adenosine receptor overexpression and functionality, as well as TNF-α levels, correlate with motor symptoms in Parkinson’s disease

(2009) Katia Varani et al.   FASEB JOURNAL

Progression of Parkinson's disease in the clinical phase: potential markers

(2009) Walter Maetzler et al.   LANCET NEUROLOGY

Adenosine, adenosine A2A antagonists, and Parkinson's disease

(2009) P. Jenner et al.   PARKINSONISM & RELATED DISORDERS

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Are adenosine antagonists, such as istradefylline, caffeine, and chocolate, useful in the treatment of Parkinson's disease?

(2008) Joseph Jankovic   ANNALS OF NEUROLOGY

Adenosine A2Areceptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson's disease: A double-blind, randomized, multicenter clinical trial (6002-US-005)

(2008) Peter A. LeWitt et al.   ANNALS OF NEUROLOGY

Adenosine as a neuromodulator in neurological diseases

(2007) D BOISON   CURRENT OPINION IN PHARMACOLOGY